As an animal health stakeholder, Virbac designs, manufactures and sells veterinary medicines, vaccines, and general health products to prevent disease and improve animal well-being and health. The quality of products and services is essential in the eyes of stakeholders, who are veterinarians, farmers and animal owners.
- The societal challenge related to the health of food producing animals is to contribute to a worldwide supply of meat and milk that is more abundant, of higher quality and less expensive. The goal is to meet the steadily increasing quantitative and qualitative food demands of a fast-growing global population that wants to eat better.
- The challenge related to companion animals is to offer veterinarians and animal owners medicines, vaccines, health products and a petfood range tailored to carnivores (in keeping with the animals’ needs) and that prolong the lives of animals and improve their quality of life. This in turn contributes to the improved well-being of the owners and is of particular benefit to people who live alone.
In order to meet these major challenges, Virbac has defined a strategy aimed at ensuring the quality of its products and services, improving the quality of life and health of animals while ensuring the comfort and safety of those who administer these products: veterinarians, farmers and animal owners. This strategy is based on two tenets; first, attaining an irreproachable level of regulatory compliance as a policy principle at every stage in the manufacturing of our products, and secondly, a monitoring and quality assurance body that ensures proper application of this policy principle on Group sites as well as those of strategic partners.
The key risk associated with this challenge would be producing medicines or vaccines of inadequate pharmaceutical quality, which could have negative effects on the health of animals and, in turn, on humans. For more information on the risks associated with this CSR challenge, please refer to the chapter on risk factors page 61 (risks related to product compliance and risks related to product liability).
To reduce exposure to this risk, and in compliance with the regulations of each country, Virbac meets the highest applicable quality-safety-efficacy standards, particularly essential for the purpose of obtaining a Marketing authorization (MA) for products. These standards involve every stage in the product life cycle, meaning before they are marketed and after they are placed on the market.
The Group’s key commitments aim at maintaining a high level of product and service quality through a “right first time” approach to reducing waste and destruction throughout the manufacturing process.
KEY ACTIONS PRIOR TO THE MARKETING PHASE
Pre-development and development phases
Purchasing and sub-contracting
Packaging and Promotion
KEY ACTIONS OCCURRING AFTER MARKET LAUNCH
Virbac monitors what happens to those veterinary medicines it places on the market in terms of safety and efficacy in accordance with related regulatory obligations:
Ongoing stability study
To ensure the efficacy over time of its pharmaceutical products that require registration, Virbac carries out ongoing research on their stability.
Virbac has had an efficient regulatory monitoring system in place for several years, allowing it to stay abreast of regulatory developments. This monitoring system is carried out through inter-professional organizations:
To ensure proper application of good practices at various stages of the product life cycle, Virbac has rolled out a dedicated Group-wide organization that covers the topics of Quality Control and Quality Assurance. Comprising more than 100 employees and spread out over various Group sites, this organization implements the Group’s quality policy based on three areas of focus: product mastery, pharmaceutical compliance and sustainable economic output.
The goal is to elevate the quality standards in compliance with and in anticipation of regulatory requirements that apply to the various research and production facilities, as well as the commercial subsidiaries, and to ensure the Group’s sustainability. In addition, this Virbac quality system allows the company to efficiently detect, trace and effectively address all quality incidents inherent to the pharmaceutical business.
KEY ACTIONS RELATED TO THE GROUP’S QUALITY STRATEGY
Securing reliable information on product quality and use
Non-compliance with regulation and voluntary codes
In 2018, out of a total of 8,333 products marketed worldwide, Virbac declared or was informed by the national authorities of 16 cases of non-compliance observed in the field. None of these cases posed any danger to animal health.
In 2017, this non-compliance number was 78 out of a total of 8,376 products marketed worldwide.
Non-compliance related to packaging
In 2018, out of a total of 8,333 product references marketed worldwide, Virbac declared or was informed by the national authorities of 8 cases of packaging non-compliance, which had no impact on product distribution.
In 2017, this non-compliance number was 21 out of a total of 8,376 product references marketed worldwide.
Non-compliance related to promotion
In 2018, out of a total of 8,333 product references marketed worldwide, Virbac declared or was informed by the national authorities of 3 communications that did not comply with regulations and codes relating to promotional marketing.
In 2017, this non-compliance number was 6 out of a total of 8,376 product references marketed worldwide.
Training employees in all manufacturing process positions
100% of employees trained.
Supporting roll-out of the Group Quality referential at all sites
100% of sites supported.